These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 15612519

  • 1. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G, Torres N, Tovar AR.
    Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
    [Abstract] [Full Text] [Related]

  • 2. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA, Piqueras L, Bishop-Bailey D.
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
    Marx N, Duez H, Fruchart JC, Staels B.
    Circ Res; 2004 May 14; 94(9):1168-78. PubMed ID: 15142970
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul 14; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 6. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
    Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, Grimaldi PA.
    Biochimie; 2004 Nov 14; 86(11):833-7. PubMed ID: 15589693
    [Abstract] [Full Text] [Related]

  • 7. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V, Viswanathan P.
    Curr Opin Investig Drugs; 2006 Oct 14; 7(10):891-7. PubMed ID: 17086933
    [Abstract] [Full Text] [Related]

  • 8. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.
    Tan NS, Michalik L, Desvergne B, Wahli W.
    J Steroid Biochem Mol Biol; 2005 Feb 14; 93(2-5):99-105. PubMed ID: 15860251
    [Abstract] [Full Text] [Related]

  • 9. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.
    Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B, Di Loreto S.
    Neuroscience; 2005 Feb 14; 130(2):325-37. PubMed ID: 15664689
    [Abstract] [Full Text] [Related]

  • 10. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
    Leisewitz AV, Urrutia CR, Martinez GR, Loyola G, Bronfman M.
    J Cell Physiol; 2008 Nov 14; 217(2):367-76. PubMed ID: 18543250
    [Abstract] [Full Text] [Related]

  • 11. Childhood obesity and insulin resistance in a Yucatan mini-piglet model: putative roles of IGF-1 and muscle PPARs in adipose tissue activity and development.
    Sébert SP, Lecannu G, Kozlowski F, Siliart B, Bard JM, Krempf M, Champ MM.
    Int J Obes (Lond); 2005 Mar 14; 29(3):324-33. PubMed ID: 15672115
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition.
    Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P.
    J Endocrinol; 2006 May 14; 189(2):199-209. PubMed ID: 16648288
    [Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC, Popeijus HE.
    Physiol Behav; 2008 May 23; 94(2):187-97. PubMed ID: 18191967
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
    Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T.
    Br J Dermatol; 2004 Oct 23; 151(4):766-75. PubMed ID: 15491415
    [Abstract] [Full Text] [Related]

  • 15. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb 23; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C, Tsantili-Kakoulidou A, Theocharis S.
    Fundam Clin Pharmacol; 2007 Jun 23; 21(3):231-44. PubMed ID: 17521292
    [Abstract] [Full Text] [Related]

  • 17. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 Jun 23; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 18. Peroxisome proliferator-activated receptors and angiogenesis.
    Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A.
    Nutr Metab Cardiovasc Dis; 2009 Dec 23; 19(11):751-9. PubMed ID: 19628379
    [Abstract] [Full Text] [Related]

  • 19. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
    Guo L, Tabrizchi R.
    Pharmacol Ther; 2006 Jul 23; 111(1):145-73. PubMed ID: 16305809
    [Abstract] [Full Text] [Related]

  • 20. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise.
    Kannisto K, Chibalin A, Glinghammar B, Zierath JR, Hamsten A, Ehrenborg E.
    Int J Mol Med; 2006 Jan 23; 17(1):45-52. PubMed ID: 16328010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.